Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
Zheng‐Hui Guan(Ministry of Education of the People's Republic of China), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), William H. H. Reece(John Radcliffe Hospital), Z. Chen(Fuzhou General Hospital of Nanjing Military Command), S Maoleekoonpairoj(Phramongkutklao Hospital), T. W. Kim(Ulsan College), Yan Wang(Jiangxi Agricultural University), V. Ratanatharathorn(Mahidol University), W S Kim(Samsung Medical Center)
Cited by 56
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388